Table of Contents Author Guidelines Submit a Manuscript
Scientifica
Volume 2013, Article ID 857519, 19 pages
http://dx.doi.org/10.1155/2013/857519
Review Article

Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management

Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue, Room 555, Pittsburgh, PA 15232, USA

Received 6 December 2012; Accepted 10 January 2013

Academic Editors: D. Jun and M. H. Manjili

Copyright © 2013 Ahmad Tarhini. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [80 citations]

The following is the list of published articles that have cited the current article.

  • Brian A. Baldo, “Adverse events to monoclonal antibodies used for cancer therapy Focus on hypersensitivity responses,” Oncoimmunology, vol. 2, no. 10, 2013. View at Publisher · View at Google Scholar
  • John C Mavropoulos, and Timothy S Wang, “Managing the skin toxicities from new melanoma drugs.,” Current treatment options in oncology, vol. 15, no. 2, pp. 281–301, 2014. View at Publisher · View at Google Scholar
  • Bing Liao, Sheetal Shroff, Carlos Kamiya-Matsuoka, and Sudhakar Tummala, “Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma.,” Neuro-oncology, vol. 16, no. 4, pp. 589–93, 2014. View at Publisher · View at Google Scholar
  • Ahmad A. Tarhini, Howard Edington, Lisa H. Butterfield, Yan Lin, Yongli Shuai, Hussein Tawbi, Cindy Sander, Yan Yin, Matthew Holtzman, Jonas Johnson, Uma N. M. Rao, and John M. Kirkwood, “Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab,” Plos One, vol. 9, no. 2, 2014. View at Publisher · View at Google Scholar
  • Lawrence Steinman, “Conflicting consequences of immunity to cancer versus autoimmunity to neurons: Insights from paraneoplastic disease,” European Journal of Immunology, vol. 44, no. 11, pp. 3201–3205, 2014. View at Publisher · View at Google Scholar
  • Giuseppina Della Vittoria Scarpati, Celeste Fusciello, Francesco Perri, Francesco Sabbatino, Soldano Ferrone, Chiara Carlomagno, and Stefano Pepe, “Ipilimumab in the treatment of metastatic melanoma: management of adverse events.,” OncoTargets and therapy, vol. 7, pp. 203–9, 2014. View at Publisher · View at Google Scholar
  • Rajasekharan Somasundaram, and Meenhard Herlyn, “Nivolumab in combination with ipilimumab for the treatment of melanoma,” Expert Review of Anticancer Therapy, vol. 15, no. 10, pp. 1135–1141, 2015. View at Publisher · View at Google Scholar
  • Lieping Chen, and Xue Han, “Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future,” Journal Of Clinical Investigation, vol. 125, no. 9, pp. 3384–3391, 2015. View at Publisher · View at Google Scholar
  • Anne Bertrand, Marie Kostine, Thomas Barnetche, Marie-Elise Truchetet, and Thierry Schaeverbeke, “Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis,” BMC Medicine, vol. 13, no. 1, 2015. View at Publisher · View at Google Scholar
  • Kara M. De Felice, Arjun Gupta, Sagar Rakshit, Sahil Khanna, Lisa A. Kottschade, Heidi D. Finnes, Konstantinos A. Papadakis, Edward V. Loftus, Laura E. Raffals, and Svetomir N. Markovic, “Ipilimumab-induced colitis in patients with metastatic melanoma,” Melanoma Research, vol. 25, no. 4, pp. 321–327, 2015. View at Publisher · View at Google Scholar
  • David Hogg, Anthony M. Joshua, Leila Khoja, Marcus Ortho Butler, and Mary Anne Chappell, “Increased treatment-related toxicity subsequent to an anti-PD-1 agent,” Current Oncology, vol. 22, no. 4, pp. E320–E322, 2015. View at Publisher · View at Google Scholar
  • Tauqeer Ahmed, Ritwik Pandey, Bhavini Shah, and Jason Black, “Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy.,” BMJ case reports, vol. 2015, 2015. View at Publisher · View at Google Scholar
  • Shannon K. Quirk, Anna K. Shure, and Devendra K. Agrawal, “Immune-mediated Adverse Effects of Anti-CTLA-4 Antibody Therapy in Metastatic Melanoma,” Translational Research, 2015. View at Publisher · View at Google Scholar
  • P. B. Araujo, M. C. A. Coelho, M. Arruda, M. R. Gadelha, and L. V. Neto, “Ipilimumab-induced hypophysitis: review of the literature,” Journal of Endocrinological Investigation, 2015. View at Publisher · View at Google Scholar
  • Stephanie A. Howard, Michael H. Rosenthal, Jyothi P. Jagannathan, Katherine M. Krajewski, Atul B. Shinagare, Nikhil H. Ramaiya, and Sree Harsha Tirumani, “Beyond the Vascular Endothelial Growth Factor Axis: Update on Role of Imaging in Nonantiangiogenic Molecular Targeted Therapies in Oncology,” American Journal Of Roentgenology, vol. 204, no. 5, pp. 919–932, 2015. View at Publisher · View at Google Scholar
  • Crescens Tiu, Carmel Pezaro, Ian D Davis, Mathis Grossmann, and Phillip Parente, “Early recognition of ipilimumab-related autoimmune hypophysitis in patients with metastatic melanoma: Case studies and recommendations for management,” Asia-Pacific Journal of Clinical Oncology, 2015. View at Publisher · View at Google Scholar
  • A Covre, S Coral, H Nicolay, G Parisi, C Fazio, F Colizzi, E Fratta, A M Di Giacomo, L Sigalotti, P G Natali, and M Maio, “Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models,” OncoImmunology, vol. 4, no. 8, pp. e1019978, 2015. View at Publisher · View at Google Scholar
  • Gwilym J. Webb, and David H. Adams, “Modeling idiosyncrasy: A novel animal model of drug-induced liver injury,” Hepatology, 2015. View at Publisher · View at Google Scholar
  • Evangelia Papavasileiou, Sashank Prasad, Suzanne K. Freitag, Lucia Sobrin, and Ann-Marie Lobo, “Ipilimumab-induced Ocular and Orbital Inflammation—A Case Series and Review of the Literature,” Ocular Immunology & Inflammation, pp. 1–7, 2015. View at Publisher · View at Google Scholar
  • S. Martin, A. M. Dudek-Peric, H. Maes, A. D. Garg, M. Gabrysiak, S. Demirsoy, J. V. Swinnen, and P. Agostinis, “Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in Vemurafenib-resistant melanoma cells,” Biochemical Pharmacology, vol. 93, no. 3, pp. 290–304, 2015. View at Publisher · View at Google Scholar
  • Krista Rubin, “Understanding Immune Checkpoint Inhibitors for Effective Patient Care,” Clinical Journal of Oncology Nursing, vol. 19, no. 6, pp. 709–717, 2015. View at Publisher · View at Google Scholar
  • A. Sahuquillo-Torralba, R. Ballester-Sánchez, C. Pujol-Marco, and R. Botella-Estrada, “Pembrolizumab, un nuevo fármaco capaz de inducir un brote psoriasis,” Actas Dermo-Sifiliográficas, 2015. View at Publisher · View at Google Scholar
  • Chintan H. Kapadia, Jillian L. Perry, Shaomin Tian, J. Christopher Luft, and Joseph M. DeSimone, “Nanoparticulate immunotherapy for cancer,” Journal of Controlled Release, 2015. View at Publisher · View at Google Scholar
  • J. Gao, Q. He, S. Subudhi, A. Aparicio, A. Zurita-Saavedra, D. H. Lee, C. Jimenez, M. Suarez-Almazor, and P. Sharma, “Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience,” Oncogene, vol. 34, no. 43, pp. 5411–5417, 2015. View at Publisher · View at Google Scholar
  • Sree Harsha Tirumani, Nikhil H. Ramaiya, Abhishek Keraliya, Nancy D. Bailey, Patrick A. Ott, F. Stephen Hodi, and Mizuki Nishino, “Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab,” Cancer Immunology Research, vol. 3, no. 10, pp. 1185–1192, 2015. View at Publisher · View at Google Scholar
  • Anja Derer, Lisa Deloch, Yvonne Rubner, Rainer Fietkau, Benjamin Frey, and Udo S. Gaipl, “Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses – Pre-Clinical Evidence and Ongoing Clinical Applications,” Frontiers in Immunology, vol. 6, 2015. View at Publisher · View at Google Scholar
  • T. Stahl, and C. Loquai, “Therapienebenwirkungen und Nachsorge bei malignem Melanom,” Der Radiologe, 2015. View at Publisher · View at Google Scholar
  • Peilin Zheng, and Zhiguang Zhou, “Human Cancer Immunotherapy with PD-1/PD-L1 Blockade.,” Biomarkers in cancer, vol. 7, no. Suppl2, pp. 15–8, 2015. View at Publisher · View at Google Scholar
  • Darrin Bann, Daniel Deschler, and Neerav Goyal, “Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma,” Cancers, vol. 8, no. 10, pp. 87, 2016. View at Publisher · View at Google Scholar
  • Magalie P. Tardy, Lauris Gastaud, Annick Boscagli, Frederic Peyrade, Andrea Gallamini, and Antoine Thyss, “Autoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case report,” Hematological Oncology, 2016. View at Publisher · View at Google Scholar
  • Brian A. Baldo, and Brian A. Baldo, “Monoclonal Antibodies Approved for Cancer Therapy,” Safety of Biologics Therapy, pp. 57–140, 2016. View at Publisher · View at Google Scholar
  • Jennifer Peterson, and Susan Steele-Moses, “Update on New Therapies With Immune Checkpoint Inhibitors,” Clinical Journal of Oncology Nursing, vol. 20, no. 4, pp. 405–410, 2016. View at Publisher · View at Google Scholar
  • Viktor H. Koelzer, Tobias Buser, Niels Willi, Sacha I. Rothschild, Andreas Wicki, Peter Schiller, Gieri Cathomas, Alfred Zippelius, and Kirsten D. Mertz, “Grover’s-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy,” Journal for ImmunoTherapy of Cancer, vol. 4, no. 1, 2016. View at Publisher · View at Google Scholar
  • Shane Mesko, Gottfried E Konecny, Paul C Tumeh, and Mitchell Kamrava, “Enhanced skin toxicity with concurrent ipilimumab and radiation in vaginal/vulvar melanoma: a case report and literature review,” BJR|case reports, pp. 20160002, 2016. View at Publisher · View at Google Scholar
  • Simon Pernot, Toulsie Ramtohul, and Julien Taieb, “Checkpoint inhibitors and gastrointestinal immune-related adverse events,” Current Opinion in Oncology, vol. 28, no. 4, pp. 264–268, 2016. View at Publisher · View at Google Scholar
  • Joëlle Antoun, Cherif Titah, and Isabelle Cochereau, “Ocular and orbital side-effects of checkpoint inhibitors,” Current Opinion in Oncology, vol. 28, no. 4, pp. 288–294, 2016. View at Publisher · View at Google Scholar
  • F. C. Fierz, F. Meier, K. Chaloupka, and C. Boeni, “Intraocular Inflammation Associated with New Therapies for Cutaneous Melanoma - Case Series and Review,” Klinische Monatsblatter Fur Augenheilkunde, vol. 233, no. 4, pp. 540–544, 2016. View at Publisher · View at Google Scholar
  • N. Stjepanovic, J. P. Velazquez-Martin, and P. L. Bedard, “Ocular toxicities of MEK inhibitors and other targeted therapies,” Annals of Oncology, vol. 27, no. 6, pp. 998–1005, 2016. View at Publisher · View at Google Scholar
  • A. Sahuquillo-Torralba, R. Ballester-Sánchez, C. Pujol-Marco, and R. Botella-Estrada, “Pembrolizumab: a New Drug That Can Induce Exacerbations of Psoriasis,” Actas Dermo-Sifiliográficas (English Edition), 2016. View at Publisher · View at Google Scholar
  • Baofu Zhang, Weina Zhao, Huizhong Li, Yuanyuan Chen, Hui Tian, Liantao Li, Longzhen Zhang, Chao Gao, and Junnian Zheng, “Immunoreceptor TIGIT inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with CD155,” Cancer Immunology, Immunotherapy, 2016. View at Publisher · View at Google Scholar
  • Leila Khoja, Eshetu G. Atenafu, Qian Ye, Craig Gedye, Maryanne Chappell, David Hogg, Marcus O. Butler, and Anthony M. Joshua, “Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma,” Oncology Letters, vol. 11, no. 2, pp. 1581–1585, 2016. View at Publisher · View at Google Scholar
  • Lindsey K. Collins, M. Shane Chapman, Joi B. Carter, and Faramarz H. Samie, “Cutaneous adverse effects of the immune checkpoint inhibitors,” Current Problems in Cancer, 2016. View at Publisher · View at Google Scholar
  • Ross A. Miller, Tara N. Miller, and Philip T. Cagle, “PD-1/PD-L1, Only a Piece of the Puzzle,” Archives of Pathology & Laboratory Medicine, vol. 140, no. 11, pp. 1187–1188, 2016. View at Publisher · View at Google Scholar
  • Leila Khoja, Eshetu G Atenafu, Arnoud Templeton, Ye Qye, Mary Anne Chappell, Sam Saibil, David Hogg, Marcus O Butler, and Anthony M Joshua, “The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma.,” Cancer medicine, vol. 5, no. 10, pp. 2792–2799, 2016. View at Publisher · View at Google Scholar
  • A. Vozy, and C. Coutzac, “Colite induite par les inhibiteurs de checkpoint immunitaire : anticorps anti-CTLA-4 et anticorps anti-PD-1/PDL-1,” Oncologie, 2016. View at Publisher · View at Google Scholar
  • Adam Brys, Raghavendra Gowda, Daniel Loriaux, Gavin P. Robertson, and Paul J. Mosca, “Nanotechnology-Based Strategies for Combating Toxicity and Resistance in Melanoma Therapy,” Biotechnology Advances, 2016. View at Publisher · View at Google Scholar
  • Ivar S Jensen, Emily Zacherle, Christopher M Blanchette, Jie Zhang, and Wes Yin, “Evaluating cost benefits of combination therapies for advanced melanoma.,” Drugs in context, vol. 5, pp. 212297, 2016. View at Publisher · View at Google Scholar
  • W. Boisseau, M. Touat, G. Berzero, J. Savatovsky, A. Marabelle, V. Touitou, D. Ricard, G. Malouf, and D. Psimaras, “Safety of treatment with nivolumab after ipilimumab-related meningoradiculitis and bilateral optic neuropathy,” European Journal of Cancer, vol. 83, pp. 28–31, 2017. View at Publisher · View at Google Scholar
  • Liam Friel Tremble, Patrick F. Forde, and Declan M. Soden, “Clinical evaluation of macrophages in cancer: role in treatment, modulation and challenges,” Cancer Immunology, Immunotherapy, 2017. View at Publisher · View at Google Scholar
  • Bernardo Leon Rapoport, Ronwyn van Eeden, Vincent Sibaud, Joel B. Epstein, Jean Klastersky, Matti Aapro, and Devan Moodley, “Supportive care for patients undergoing immunotherapy,” Supportive Care in Cancer, 2017. View at Publisher · View at Google Scholar
  • Stephanie T. Chang, Christine O. Menias, Meghan G. Lubner, Vincent M. Mellnick, Amy K. Hara, and Terry S. Desser, “Molecular and Clinical Approach to Intra-abdominal Adverse Effects of Targeted Cancer Therapies,” RadioGraphics, pp. 160162, 2017. View at Publisher · View at Google Scholar
  • Courtney P. Rudick, David L. Cornell, and Devendra K. Agrawal, “Single versus combined immunoregulatory approach using PD-1 and CTLA-4 modulators in controlling sepsis,” Expert Review of Clinical Immunology, pp. 1–13, 2017. View at Publisher · View at Google Scholar
  • James Larkin, Daniel Reshef, Alexandre Avila, David A Reardon, Bartosz Chmielowski, Christopher D Lao, F Stephen Hodi, William Sharfman, Jeffrey Weber, Karijn P M Suijkerbuijk, Sergio Azevedo, and Hewei Li, “Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.,” The oncologist, vol. 22, no. 6, pp. 709–718, 2017. View at Publisher · View at Google Scholar
  • Caroline Prieux-Klotz, Marie Dior, Diane Damotte, Johann Dreanic, Bertrand Brieau, Catherine Brezault, Vered Abitbol, Stanislas Chaussade, and Romain Coriat, “Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management,” Targeted Oncology, 2017. View at Publisher · View at Google Scholar
  • Peng Zhao, Djordje Atanackovic, Shuyun Dong, Hideo Yagita, Xiao He, and Mingnan Chen, “An Anti-Programmed Death-1 Antibody (αPD-1) Fusion Protein That Self-Assembles into a Multivalent and Functional αPD-1 Nanoparticle,” Molecular Pharmaceutics, 2017. View at Publisher · View at Google Scholar
  • Tala Achkar, and Ahmad A Tarhini, “The use of immunotherapy in the treatment of melanoma.,” Journal of hematology & oncology, vol. 10, no. 1, pp. 88, 2017. View at Publisher · View at Google Scholar
  • Niels J. Brouwer, John B.A.G. Haanen, and Martine J. Jager, “Development of Ocular Rosacea following Combined Ipilimumab and Nivolumab Treatment for Metastatic Malignant Skin Melanoma,” Ocular Oncology and Pathology, pp. 188–192, 2017. View at Publisher · View at Google Scholar
  • Gwendolyn J McGinnis, David Friedman, Kristina H Young, Eileen Ruth S Torres, Charles R Thomas, Michael J Gough, and Jacob Raber, “Neuroinflammatory and cognitive consequences of combined radiation and immunotherapy in a novel preclinical model.,” Oncotarget, vol. 8, no. 6, pp. 9155–9173, 2017. View at Publisher · View at Google Scholar
  • Jianhong Zhu, Junyan Wu, Guocheng Li, Jianfang Li, Yin Lin, Zhichao He, Chen Su, Wenxia Zhao, Qianqian Wu, Zepeng Chen, and Kaifeng Qiu, “Meta-analysis of randomized controlled trials for the incidence and risk of fatal adverse events in cancer patients treated with ipilimumab,” Expert Opinion on Drug Safety, pp. 1–6, 2017. View at Publisher · View at Google Scholar
  • Wen-Chun Chen, Pen-Yuan Chu, Yu-Ting Lee, Wen-Bin Lu, Chun-Yu Liu, Peter Mu-Hsin Chang, and Muh-Hwa Yang, “Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population,” Medicine, vol. 96, no. 52, pp. e9519, 2017. View at Publisher · View at Google Scholar
  • Julia Dai, Viswanath R Belum, Shenhong Wu, Vincent Sibaud, and Mario E Lacouture, “Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.,” Journal of the American Academy of Dermatology, vol. 77, no. 5, pp. 902–910.e2, 2017. View at Publisher · View at Google Scholar
  • Stefania Stucci, Raffaele Palmirotta, Anna Passarelli, Erica Silvestris, Antonella Argentiero, Laura Lanotte, Silvana Acquafredda, Annalisa Todisco, and Franco Silvestris, “Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management.,” Oncology letters, vol. 14, no. 5, pp. 5671–5680, 2017. View at Publisher · View at Google Scholar
  • Grainne M O'Kane, Catherine Labbé, Mark K Doherty, Kelvin Young, Hamzeh Albaba, and Natasha B Leighl, “Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.,” The oncologist, vol. 22, no. 1, pp. 70–80, 2017. View at Publisher · View at Google Scholar
  • S. Eldridge, and M. Davis, “Antineoplastic Agents ?,” Reference Module in Biomedical Sciences, 2017. View at Publisher · View at Google Scholar
  • Jindřich Kopecký, Ondřej Kubeček, Tomáš Geryk, Birgita Slováčková, Petr Hoffmann, Miroslav Žiaran, and Peter Priester, “Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report,” Journal of Medical Case Reports, vol. 12, no. 1, 2018. View at Publisher · View at Google Scholar
  • Leonard H. Calabrese, Cassandra Calabrese, and Laura C. Cappelli, “Rheumatic immune-related adverse events from cancer immunotherapy,” Nature Reviews Rheumatology, 2018. View at Publisher · View at Google Scholar
  • Shu Yang, and Aarti Asnani, “Cardiotoxicities Associated with Immune Checkpoint Inhibitors,” Current Problems in Cancer, 2018. View at Publisher · View at Google Scholar
  • Michael Constantin Kirchberger, and Lucie Heinzerling, “Immune-Related Adverse Toxicities and Clinical Management,” Melanoma, pp. 577–589, 2018. View at Publisher · View at Google Scholar
  • Daniel L. Suzman, Lorraine Pelosof, Amy Rosenberg, and Mark I. Avigan, “Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents,” Liver International, 2018. View at Publisher · View at Google Scholar
  • Noah A. Kolb, Christopher R Trevino, Waqar Waheed, Fatemeh Sobhani, Kara K. Landry, Alissa A. Thomas, and Mike Hehir, “Neuromuscular complications of immune checkpoint inhibitor therapy,” Muscle & Nerve, 2018. View at Publisher · View at Google Scholar
  • Carmen Belli, Massimo Zuin, Luca Mazzarella, Dario Trapani, Paolo D’Amico, Elena Guerini-Rocco, Bruno Achutti Duso, and Giuseppe Curigliano, “Liver Toxicity in the Era of Immune Checkpoint Inhibitors: A Practical Approach,” Critical Reviews in Oncology/Hematology, 2018. View at Publisher · View at Google Scholar
  • Ahmad Tarhini, Yan Lin, Huang Lin, Zahra Rahman, Priyanka Vallabhaneni, Prateek Mendiratta, James F. Pingpank, Matthew P. Holtzman, Erik C. Yusko, Julie A. Rytlewski, Uma N. M. Rao, Robert L. Ferris, and John M. Kirkwood, “Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire,” Journal for ImmunoTherapy of Cancer, vol. 6, no. 1, 2018. View at Publisher · View at Google Scholar
  • Dana Alsaadi, Neil J. Shah, Aline Charabaty, and Michael B. Atkins, “A case of checkpoint inhibitor-induced celiac disease,” Journal for ImmunoTherapy of Cancer, vol. 7, no. 1, 2019. View at Publisher · View at Google Scholar
  • Marcus A. Couey, R. Bryan Bell, Ashish A. Patel, Meghan C. Romba, Marka R. Crittenden, Brendan D. Curti, Walter J. Urba, and Rom S. Leidner, “Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance,” Journal for ImmunoTherapy of Cancer, vol. 7, no. 1, 2019. View at Publisher · View at Google Scholar
  • Khor Zhong Wei, Mark Baxter, and Richard Casasola, “Hypophysitis induced by immune checkpoint inhibitors in a Scottish melanoma population,” Melanoma Management, 2019. View at Publisher · View at Google Scholar
  • Andreas Teufel, Tianzuo Zhan, Nicolai Härtel, Jan Bornschein, Matthias P. Ebert, and Nadine Schulte, “Management of Immune Related Adverse Events induced by Immune Checkpoint Inhibition,” Cancer Letters, 2019. View at Publisher · View at Google Scholar
  • Joseph J. Jennings, Rohan Mandaliya, Ahmad Nakshabandi, and James H. Lewis, “Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies,” Expert Opinion on Drug Metabolism & Toxicology, pp. 1–14, 2019. View at Publisher · View at Google Scholar
  • Aniruddh Som, Rohan Mandaliya, Dana Alsaadi, Maham Farshidpour, Aline Charabaty, Nidhi Malhotra, and Mark C Mattar, “Immune checkpoint inhibitor-induced colitis: A comprehensive review,” World Journal of Clinical Cases, vol. 7, no. 4, pp. 405–418, 2019. View at Publisher · View at Google Scholar
  • Kerasia-Maria Plachouri, Eleftheria Vryzaki, and Sophia Georgiou, “Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview,” Current Drug Safety, vol. 14, no. 1, pp. 14–20, 2019. View at Publisher · View at Google Scholar
  • Alvaro Moreira, Carmen Loquai, Claudia Pföhler, Katharina C. Kähler, Samuel Knauss, Markus V. Heppt, Ralf Gutzmer, Florentia Dimitriou, Friedegund Meier, Heidrun Mitzel-Rink, Gerold Schuler, Patrick Terheyden, Kai-Martin Thoms, Matthias Türk, Reinhard Dummer, Lisa Zimmer, Rolf Schröder, and Lucie Heinzerling, “Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors,” European Journal of Cancer, vol. 106, pp. 12–23, 2019. View at Publisher · View at Google Scholar